Present and Future of Epigenetics in Prostate Cancer: Therapeutic Opportunities and Translational Approaches

Prostate cancer (PCa) is among the most diagnosed malignancies worldwide and is a leading cause of cancer-related mortality, with clinical management complicated by biological heterogeneity. Epigenetic alterations (including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA regulation) are increasingly recognized as key drivers of PCa initiation, progression, and therapeutic resistance. In early-stage disease, for example, the hypermethylation of promoter regions silencing tumor suppressor genes represents one of the earliest oncogenic events. During progression to castration-resistance, epigenetic mechanisms modulate androgen receptor signaling through chromatin remodeling complexes, DNA demethylation regulators, and histone-modifying enzymes. In therapy-induced neuroendocrine prostate cancer (t-NEPC), an even more aggressive form of PCa, dynamic epigenetic reprogramming, driven by chromatin-modifying enzymes and metabolic-epigenetic crosstalk, underlies lineage plasticity and transdifferentiation from adenocarcinoma. Pharmacological targeting of epigenetic regulators has been explored across multiple drug classes and clinical settings, though development remains limited compared to other malignancies; certain inhibitor classes are more clinically advanced than others, while dedicated trials in particularly NEPC remain scarce. Epigenetic biomarkers, detectable in tissue, blood, and urine, show promise for diagnosis, prognosis, and risk stratification, with multi-marker signatures outperforming individual markers. Translational advances (including bisulfite-based methylation assays, liquid biopsy platforms, single-cell/multi-region sequencing, and transcriptomic classifiers) are progressively enabling clinical application. Despite this progress, intratumoral heterogeneity, lack of standardization, and insufficient prospective validation continue to hinder routine implementation, underscoring the need for integrated multi-omic approaches in future PCa precision medicine.

Authors

Publication Details

Journal
Cancers
Published
2026-11-13
DOI
https://doi.org/10.3390/cancers18223632
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Present and Future of Epigenetics in Prostate Cancer: Therapeutic Opportunities and Translational Approaches

Sabrina Marini, Cristian Lolli, Alice Rossi, Silvia Palmerio et al.
Cancers
Prostate Cancer Treatment and Research
article

Present and Future of Epigenetics in Prostate Cancer: Therapeutic Opportunities and Translational Approaches

Sabrina Marini, Cristian Lolli, Alice Rossi, Silvia Palmerio, Francesca Zacchi, Irene Torresan, Andrea Zivi, Ester Tasselli, Michele Rota
article en

Abstract

Prostate cancer (PCa) is among the most diagnosed malignancies worldwide and is a leading cause of cancer-related mortality, with clinical management complicated by biological heterogeneity. Epigenetic alterations (including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA regulation) are increasingly recognized as key drivers of PCa initiation, progression, and therapeutic resistance. In early-stage disease, for example, the hypermethylation of promoter regions silencing tumor suppressor genes represents one of the earliest oncogenic events. During progression to castration-resistance, epigenetic mechanisms modulate androgen receptor signaling through chromatin remodeling complexes, DNA demethylation regulators, and histone-modifying enzymes. In therapy-induced neuroendocrine prostate cancer (t-NEPC), an even more aggressive form of PCa, dynamic epigenetic reprogramming, driven by chromatin-modifying enzymes and metabolic-epigenetic crosstalk, underlies lineage plasticity and transdifferentiation from adenocarcinoma. Pharmacological targeting of epigenetic regulators has been explored across multiple drug classes and clinical settings, though development remains limited compared to other malignancies; certain inhibitor classes are more clinically advanced than others, while dedicated trials in particularly NEPC remain scarce. Epigenetic biomarkers, detectable in tissue, blood, and urine, show promise for diagnosis, prognosis, and risk stratification, with multi-marker signatures outperforming individual markers. Translational advances (including bisulfite-based methylation assays, liquid biopsy platforms, single-cell/multi-region sequencing, and transcriptomic classifiers) are progressively enabling clinical application. Despite this progress, intratumoral heterogeneity, lack of standardization, and insufficient prospective validation continue to hinder routine implementation, underscoring the need for integrated multi-omic approaches in future PCa precision medicine.

CancersVol. 18(22)
Good health and well-being
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon